{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T15:32:22Z","timestamp":1770478342887,"version":"3.49.0"},"reference-count":17,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2004,10,8]],"date-time":"2004-10-08T00:00:00Z","timestamp":1097193600000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2004,10]]},"abstract":"<jats:sec>\n                    <jats:label\/>\n                    <jats:p>Section Editor<\/jats:p>\n                    <jats:p>Michael G. Wyllie<\/jats:p>\n                    <jats:p>Panel of Advisors<\/jats:p>\n                    <jats:p>Ian Eardley, UK<\/jats:p>\n                    <jats:p>Jean Fourcroy, USA<\/jats:p>\n                    <jats:p>Sidney Glina, Brazil<\/jats:p>\n                    <jats:p>Julia Heiman, USA<\/jats:p>\n                    <jats:p>Chris McMahon, Australia<\/jats:p>\n                    <jats:p>Bob Millar, UK<\/jats:p>\n                    <jats:p>Alvaro Morales, Canada<\/jats:p>\n                    <jats:p>Michael Perelman, USA<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To evaluate, in a randomized, double\u2010blind, placebo\u2010controlled, multicentre trial, the safety and efficacy of on\u2010demand tadalafil (an oral phosphodiesterase type\u20105 inhibitor approved in many countries for treating erectile dysfunction, ED) in a Western European population of men with mild\u2010to\u2010severe ED.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>Patients were randomized according to baseline severity of ED in a ratio of 3\u2003: 1 to receive either tadalafil 20\u2003mg or placebo for 12\u2003weeks. Primary efficacy endpoints were mean changes from baseline to endpoint (12\u2003weeks) in the erectile function (EF) domain of the International Index of Erectile Function (IIEF) and percentages of \u2018Yes\u2019 responses to Sexual Encounter Profile (SEP) diary Question 2 (\u2018Were you able to insert your penis into your partner's vagina?\u2019) and Question 3 (\u2018Did your erection last long enough for you to have successful intercourse?\u2019). Secondary endpoints included mean changes from baseline to endpoint in IIEF Intercourse Satisfaction and Overall Satisfaction domains, selected questions of the IIEF, and the percentage of \u2018Yes\u2019 responses to Global Assessment Questions (GAQ) at the last visit. Other analyses included the percentage of patients in each treatment group at endpoint with IIEF EF domain scores in the normal range (&gt;26), the frequency of intercourse attempts and mean per\u2010patient intercourse success rate at various times after dosing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      The mean age of the patients was 53\u2003years and 80% had a history of ED of \u2265\u200a1\u2003year. The mean baseline EF domain score was 13.5, with 40.5% of patients in the severe category. Tadalafil improved mean EF domain scores by 11.1, vs 0.4 for placebo (\n                      <jats:italic>P<\/jats:italic>\n                      \u2003&lt;\u20030.001). In addition, 73.9% of sexual intercourse attempts were successful (SEP\u2010Q3) in tadalafil\u2010treated patients, compared with 29.9% in placebo\u2010treated patients during the period after baseline (\n                      <jats:italic>P<\/jats:italic>\n                      \u2003&lt;\u20030.001). Tadalafil significantly improved the mean IIEF intercourse satisfaction (5.1, tadalafil; 1.1, placebo) and overall satisfaction domain scores (3.9, tadalafil; 0.5, placebo),\n                      <jats:italic>P<\/jats:italic>\n                      \u2003&lt;\u20030.001. GAQs used to assess the overall effect of the treatment indicated that tadalafil was superior to placebo (\n                      <jats:italic>P<\/jats:italic>\n                      \u2003&lt;\u20030.001) in improving erections (82.1%, tadalafil; 23.1%, placebo) and sexual activity (78.6% and 17.3%). The most common treatment\u2010emergent adverse events more frequent (&gt;2%) with tadalafil than placebo were headache, dyspepsia, flushing, back pain, pain in limb and myalgia. These adverse events were mostly mild to moderate.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Tadalafil improved erectile function and was well tolerated when taken by men from Western Europe with mild\u2010to\u2010severe ED.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2004.05049.x","type":"journal-article","created":{"date-parts":[[2004,10,8]],"date-time":"2004-10-08T04:40:37Z","timestamp":1097210437000},"page":"871-877","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction"],"prefix":"10.1111","volume":"94","author":[{"given":"Ian","family":"Eardley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edoardo","family":"Austoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoff","family":"Hackett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danilo","family":"Lembo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Beardsworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,10,8]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3900567"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)34871-1"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.1999.00142.x"},{"key":"e_1_2_8_5_2","unstructured":"Anonymous. Impotence. NIH Consensus Statement1992; 10:1\u201331"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3900631"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64442-4"},{"issue":"5","key":"e_1_2_8_8_2","article-title":"The effect of intrinsic and extrinsic factors on the pharmacokinetic properties of tadalafil (IC351)","volume":"13","author":"Patterson B","year":"2001","journal-title":"Int J Impot Res"},{"issue":"5","key":"e_1_2_8_9_2","first-page":"S62","article-title":"Dose normalized PK of single\u2010dose tadalafil (IC351) in healthy volunteers","volume":"13","author":"Patterson B","year":"2001","journal-title":"Int J Impot Res"},{"key":"e_1_2_8_10_2","volume-title":"Cialis (IC351) Provides Prompt Response and Extended Period of Responsiveness for the Treatment of Men with Erectile Dysfunction (ED)","author":"Padma\u2010Nathan H","year":"2001"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(03)00359-5"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3900857"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(00)00697-X"},{"key":"e_1_2_8_14_2","volume-title":"Erectile Dysfunction: 1st International Consultation on Erectile Dysfunction.","author":"Rosen R","year":"2000"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(97)00238-0"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(99)00099-0"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000063377.12281.57"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005392-199805000-00037"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2004.05049.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2004.05049.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:08:23Z","timestamp":1761728903000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2004.05049.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,10]]}},"alternative-id":["10.1111\/j.1464-410X.2004.05049.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2004.05049.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,10]]},"assertion":[{"value":"2004-10-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}